Alkermes plc ALKS
Updated: 10 Sep 2026
No signal published yet
We already track Alkermes and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Alkermes plc? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Alkermes free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 24, 2026, The Lancet Neurology published positive Phase 2 data from the Vibrance-1 study evaluating alixorexton in adults with narcolepsy type 1. Previously on July 28, 2026, the company reported second-quarter 2026 revenues of $496.0 million, driven by product sales following its acquisition of Avadel Pharmaceuticals.
What Firelda Watch includes for Alkermes plc
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Alkermes plc? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Alkermes free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more